CN107714823A - A kind of pharmaceutical composition of reducing blood lipid - Google Patents
A kind of pharmaceutical composition of reducing blood lipid Download PDFInfo
- Publication number
- CN107714823A CN107714823A CN201711082773.9A CN201711082773A CN107714823A CN 107714823 A CN107714823 A CN 107714823A CN 201711082773 A CN201711082773 A CN 201711082773A CN 107714823 A CN107714823 A CN 107714823A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- reducing blood
- blood lipid
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition of reducing blood lipid, pharmaceutical composition includes following raw material：Radix bupleuri, Huang Shi, mulberry leaf, the root of kudzu vine, Poria cocos, the red sage root, radix glycyrrhizae, franchet groundcherry persistent calyx or fruit, radish seed, ROUFURONG.The beneficial effects of the invention are as follows each raw material to be prepared using natural drug, each component compounding use, greatly improves the hypolipemic function of the pharmaceutical composition, and curative effect is fast, and cost is low, and has no toxic side effect.
Description
Technical field
The present invention relates to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition that can reduce human body lipids contents.
Background technology
Along with the quickening of process of industrialization, the material life of people is greatly improved, and the mankind enjoy economic hair
While opening up the material progress brought, also increasingly feel material enjoyment and bring the misfortune of people approaching.Due to itself
High fat of blood caused by bad life-form structure has turned into the main threatening factors of modern disease.Artery caused by hyperlipidemia is athero-
Hardening is the main reason for causing coronary heart disease, hypertension and cardiovascular and cerebrovascular disease.
At present treatment high fat of blood mainly take Western medicine, Western medicine lipid-lowering medicine mainly has two major classes, with reduce T-CHOL and
First-elected Statins based on low-density lipoprotein and to reduce the fibrates based on triglycerides, the positive effect of its lipid-loweringing, but
The side effect such as hepatorenal damage and serious myopathy can be caused, easily cause complication etc..
China, substantial amounts of research work is have also been made in Chinese herb prevention hyperlipemia at present, at present existing a variety of reduction blood fat
Chinese medicine preparation, such as：YunNan Pollen Tiendni Oral liquid, xinqingning tablet, fat can clearly, shou wu pian, SHANZHAJING JIANGZHI PIAN, lipid-loweringing
The kind more than ten such as body-building piece, xinmaitong tablet, Jiangzhiling Pian, hypogastric lipid-lowering pill, capsule of ginkgo leaves, there is a constant current modulation to reducing blood fat
Effect, but phase length is taken effect, and DeGrain.
The content of the invention
The technical problems to be solved by the invention are to provide a kind of pharmaceutical composition of reducing blood lipid, and it is high to make up existing treatment
The deficiency of hypolipidemic medicine.
The technical scheme that the present invention solves above-mentioned technical problem is as follows：
A kind of pharmaceutical composition of reducing blood lipid, described pharmaceutical composition include following raw material：Radix bupleuri, Huang Shi, mulberry leaf, Pueraria lobota
Root, Poria cocos, the red sage root, radix glycyrrhizae, franchet groundcherry persistent calyx or fruit, radish seed, ROUFURONG.
The beneficial effects of the invention are as follows：By the compatibility and coordinative role of each raw material, body is integrated on the whole
Conditioning, reach nourishing liver and kidney, eliminating the phlegm dehumidifying, reinforcing spleen to promote digestion, clearing and activating the channels and collaterals, activating vessels, scattered stasis, change turbid lipid-loweringing, invigorating the spleen
Nourishing heart, help spleen nourishing the stomach, benefiting qi and nourishing blood, promote blood to follow bad, strengthen immunity, constitutional effect, and then can have
Effect reduces blood fat, reduces the content of T-CHOL in serum, triglycerides, HDL and low-density lipoprotein, clearly
Except vascular wall cholesterol, alleviate atherosclerosis, anti-lipid peroxidation, realize the purpose of reducing blood lipid.
On the basis of above-mentioned technical proposal, the present invention can also do following improvement.
Further, each raw material of described pharmaceutical composition is formed by following parts by weight：Radix bupleuri 20-35 parts, Huang Shi 15-30
Part, mulberry leaf 10-25 parts, root of kudzu vine 10-20 parts, Poria cocos 10-20 parts, red sage root 10-15 parts, radix glycyrrhizae 10-15 parts, franchet groundcherry persistent calyx or fruit 5-10 parts,
Radish seed 5-10 parts, ROUFURONG 5-10 parts.
Beneficial effect using above-mentioned further scheme is the selected each raw material of the pharmaceutical composition and its proportioning, by each
The compatibility and coordinative role of raw material so that therapeutic effect significantly improves.
Further, each raw material of described pharmaceutical composition is formed by following parts by weight：25 parts of radix bupleuri, 25 parts of Huang Shi, mulberry leaf
20 parts, 15 parts of the root of kudzu vine, 15 parts of Poria cocos, 13 parts of the red sage root, 13 parts of radix glycyrrhizae, 8 parts of franchet groundcherry persistent calyx or fruit, 8 parts of radish seed, 8 parts of ROUFURONG.
Beneficial effect using above-mentioned further scheme is the effective ingredient maximum limit of each raw material under this conditions of mixture ratios
Its effect of the performance of degree, the effect of reducing blood lipid are particularly evident.
Further, application of the described pharmaceutical composition in the medicine for preparing prevention and/or treatment hyperlipemia.
Beneficial effect using above-mentioned further scheme is to be applied to prevent and/or treat in hyperlipemia, can be effective
Reduce the content of human body blood fat.
Further, the formulation of described pharmaceutical composition is granule, tablet, pulvis, paste, capsule etc., preferred dosage form
For granule.
Beneficial effect using above-mentioned further scheme be can be made on the premise of curative effect is ensured facilitate it is easy-to-use each
Kind formulation, such as granule, tablet, pulvis, paste, capsule, and there is simple preparation technology, good effect, without any secondary work
The advantages that with, convenient to take and application easy to spread.
Further, the preparation method of the Antilipidemic pharmaceutical compositions granule comprises the following steps：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
The correlation properties of each raw material are as follows in the present invention：
Radix bupleuri：Bitter, cold nature, enter liver, kidney two warp.Main component is bupleurumol, the black alcohol of plant, aliphatic acid, radix bupleuri soap
Glucoside, have and dredge gas, Xie Yu, dissipate effect of fire.Wherein saikosaponin saikoside has the function that reducing blood lipid.
The Radix Astragali, it is leguminous herbaceous plant's astragalus mongolicus, the root of Astragalus membranacus.It is sweet, tepor.Return lung, the spleen channel, have tonifying Qi to consolidate
Table, diuretic and maintain drug, the function of expelling pus and promoting granulation, containing flavones ingredient, also containing compositions such as astragalus saponin I, V, III, polysaccharide.Grind
Study carefully and show that astragalus decoction can reduce Triglycerides in Serum, T-CHOL, low-density lipoprotein content, consolidated with reducing total courage
More prominent (the P of alcohol effect<0.01), while there is the trend of increasing high density lipoprotein, the results showed that astragalus decoction has drop
The effect of fat, antiatherosclerosis.
Mulberry leaf：In modern times, doctor trained in Western medicine is using mulberry leaf and mulberry leaf biological agent as improving diabetes and other various difficult and complicated cases
Medicine and use, it is believed that its drug effect is extremely wide.There are clearing away the lungheat and moisturizing, cough-relieving, reduce phlegm and internal heat, resolving sputum, control night sweat；Tonifying liver, clearing liver are bright
Mesh, treatment is dizzy, has a sleepless night, eliminates eye strain；Subside a swelling, purify the blood, treatment dysentery, stomachache, fat-reducing, except tinea pedis, profit it is big,
Small intestine；Resisting stress, cool blood, lowering blood pressure and blood fat, prevention miocardial infarction, cerebral hemorrhage, dispel headache, long hair；Hypoglycemic, anti-sugar disease
Deng.
The root of kudzu vine：Dry, it is sweet, pungent, it is cool, there is expelling pathogenic factors from muscles and skin to bring down a fever, promoting eruption, promote the production of body fluid to quench thirst, the work(of Shengyang Zhixie.It is usually used in exterior syndrome
Heating, stiff nape and back, measles without adequate eruption, pyreticosis is thirsty, and the deficiency of Yin is quenched one's thirst, and heat is purged heat dysentery, splenasthenic diarrhea.
Poria cocos：It is sweet, light, thoughts of returning home warp, lung channel, the spleen channel, kidney channel, clearing damp and promoting diuresis, invigorating the spleen calming heart；《Book on Chinese herbal medicine is just》Saying can profit
Surreptitiously dry, profit steals then happy intelligence development, leads turbid promote the production of body fluid；Dry, dry spleen of relieving oedema or abdominal distension through diuresis or purgation, bowl spares stomach invigorating.
The red sage root：For labiate red sage root dry root and rhizome.The property of medicine：Bitter；Cold nature.Channel tropism：The thoughts of returning home, Liver Channel.Tool
There is promoting blood circulation, inducing meastruation to relieve menalgia, relieving restlessness that clears away heart-fire, the effect of cool blood to disappear carbuncle.Cure mainly：For chest impediment and cardialgia, gastral cavity abdomen hypochondriac pain , Disorder lumps in the abdomen
Accumulation, hot numbness pain, dysphoria and insomnia, irregular menstruation, dysmenorrhoea Amenorrhea, sore Ulcers swelling and pain.
Radix glycyrrhizae：For the dry root and rhizome of glycyrrhizic legume, swollen fruit Radix or glycyrrhiza glabra.Nature and flavor are sweet, put down.The thoughts of returning home,
Lung, spleen, stomach.Function：With , Cheongju thermal detoxifications of invigorating the spleen and benefiting qi, expelling phlegm and arresting coughing, relieving spasm to stop pain, the work(of coordinating the drug actions of a prescription.Cure mainly：With
In weakness of the spleen and the stomach, lassitude hypodynamia, palpitation, coughing with a lot of sputum, gastral cavity abdomen, four limbs contraction, carbuncle sore tumefacting virus, alleviate medicine poison
It is property, strong.
Franchet groundcherry persistent calyx or fruit：It is sour, sweet, tremble with fear.Lung, kidney channel.With removing heat from the lung and relieving sorethroat, the effect of resolving sputum profit water.For lung heat productive cough, pharynx
Larynx swells and ache, and hectic fever due to yin labor heat, urine leaching is puckery, day blister wet sore.
Radish seed：Gas is micro-, lightly seasoned, slight bitter is pungent.For being dried to for crucifer radish Raphanus sativus L.
Ripe seed.Plant is tapped during summer fruit maturation, is dried, rubs seed, removes impurity, then dry.
ROUFURONG：It is sweet, salty, it is warm-natured, return kidney, large intestine channel, kidney-replenishing, benefiting essence-blood, ease constipation road；Main decline of kidney-YANG, essence and blood
The impotence of deficiency, seminal emission, gonorrhoea, the frequent micturition heeltap, pain in the back flaccidity of lower limbs, tinnitus mesh flower, menstruation are spread out the phase, fertility, dry constipation of intestines.
Embodiment
The principle and feature of the present invention are described below in conjunction with specific embodiment, example is served only for explaining this
Invention, is not intended to limit the scope of the present invention.
Embodiment 1
The present embodiment provides a kind of pharmaceutical composition of reducing blood lipid, including following parts by weight of component：25 parts of radix bupleuri, Huang Shi
25 parts, 20 parts of mulberry leaf, 15 parts of the root of kudzu vine, 15 parts of Poria cocos, 13 parts of the red sage root, 13 parts of radix glycyrrhizae, 8 parts of franchet groundcherry persistent calyx or fruit, 8 parts of radish seed, ROUFURONG
8 parts.
Granule is made in above-mentioned Antilipidemic pharmaceutical compositions, and specific preparation process is as follows：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
Embodiment 2
The present embodiment provides a kind of pharmaceutical composition of reducing blood lipid, including following parts by weight of component：20 parts of radix bupleuri, Huang Shi
30 parts, 10 parts of mulberry leaf, 20 parts of the root of kudzu vine, 20 parts of Poria cocos, 10 parts of the red sage root, 10 parts of radix glycyrrhizae, 10 parts of franchet groundcherry persistent calyx or fruit, 10 parts of radish seed, meat cottonrose hibiscus
5 parts of Rong.
Granule is made in above-mentioned Antilipidemic pharmaceutical compositions, and specific preparation process is as follows：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
Embodiment 3
The present embodiment provides a kind of pharmaceutical composition of reducing blood lipid, including following parts by weight of component：35 parts of radix bupleuri, Huang Shi
15 parts, 25 parts of mulberry leaf, 10 parts of the root of kudzu vine, 10 parts of Poria cocos, 15 parts of the red sage root, 15 parts of radix glycyrrhizae, 5 parts of franchet groundcherry persistent calyx or fruit, 50 parts of radish seed, meat cottonrose hibiscus
10 parts of Rong.
Granule is made in above-mentioned Antilipidemic pharmaceutical compositions, and specific preparation process is as follows：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
The pharmaceutical composition of the reducing blood lipid provided in inventive formulation, clinical practice show that therapeutic effect is not obvious
Difference, all it is the medicinal granule for being arbitrarily derived from embodiment 1-3 preparations in treatment use.
Comparative example 1
A kind of pharmaceutical composition for reducing blood lipid that this comparative example provides, including following parts by weight of component：20 parts of radix bupleuri, mulberry
10 parts of leaf, 20 parts of the root of kudzu vine, 20 parts of Poria cocos, 10 parts of the red sage root, 10 parts of radix glycyrrhizae, 10 parts of franchet groundcherry persistent calyx or fruit, 10 parts of radish seed, 5 parts of ROUFURONG.
Granule is made in above-mentioned Antilipidemic pharmaceutical compositions, and specific preparation process is as follows：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
A kind of pharmaceutical composition for reducing blood lipid that 2 comparative examples of comparative example provide, including following parts by weight of component：Huang Shi
30 parts, 10 parts of mulberry leaf, 20 parts of the root of kudzu vine, 20 parts of Poria cocos, 10 parts of the red sage root, 10 parts of radix glycyrrhizae, 10 parts of franchet groundcherry persistent calyx or fruit, 10 parts of radish seed, meat cottonrose hibiscus
5 parts of Rong.
Granule is made in above-mentioned Antilipidemic pharmaceutical compositions, and specific preparation process is as follows：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
Comparative example 3
A kind of pharmaceutical composition for reducing blood lipid that this comparative example provides, including following parts by weight of component：20 parts of radix bupleuri, Huang
30 parts of family name, 20 parts of the root of kudzu vine, 20 parts of Poria cocos, 10 parts of the red sage root, 10 parts of radix glycyrrhizae, 10 parts of franchet groundcherry persistent calyx or fruit, 10 parts of radish seed, 5 parts of ROUFURONG.
Granule is made in above-mentioned Antilipidemic pharmaceutical compositions, and specific preparation process is as follows：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
300 hyperlipemias are persistently taken with the Antilipidemic pharmaceutical compositions described in above-described embodiment 2 after one month
Situation be tracked observation, itself take it is front and rear contrasted, find after testing, wherein there is 98.9%-99.7% high blood
The content of the HDL (HDL) of fat disease patient's body, T-CHOL (TC) and triglycerides (TG) is decreased obviously,
Wherein HDL (HDL) averagely declines 0.54mmol/L, and T-CHOL (TC) averagely declines 2.99mmol/L, glycerine
Three esters (TG) averagely decline 1.66mmol/L.In addition, respectively 100 are persistently taken with comparative example 1, comparative example 2 and contrast
The hyperlipemia of the antilipemic Chinese herbal medicine medicinal powder of example 3 is tracked observation, after taking one month, takes in the reducing blood lipid of comparative example 1
Under the content of the HDL (HDL) of the patient's body of medicine medicinal powder, T-CHOL (TC) and triglycerides (TG) is obvious
Drop, wherein HDL (HDL) averagely declines 0.44mmol/L, and T-CHOL (TC) averagely declines 2.59mmol/L, sweet
Oily three esters (TG) averagely decline 1.56mmol/L；Take the high density fat of the patient's body of the antilipemic Chinese herbal medicine medicinal powder of comparative example 2
The content of albumen (HDL), T-CHOL (TC) and triglycerides (TG) is decreased obviously, and wherein HDL (HDL) is flat
Decline 0.47mmol/L, T-CHOL (TC) averagely declines 2.55mmol/L, and triglycerides (TG) averagely declines
1.50mmol/L；Take HDL (HDL), the T-CHOL of the patient's body of the antilipemic Chinese herbal medicine medicinal powder of comparative example 1
(TC) and the content of triglycerides (TG) is decreased obviously, and wherein HDL (HDL) averagely declines 0.42mmol/L,
T-CHOL (TC) averagely declines 2.39mmol/L, and triglycerides (TG) averagely declines 1.46mmol/L.Contrasting above-mentioned data can
See, antilipemic Chinese herbal medicine medicinal powder provided by the invention formula advantages of simple, especially radix bupleuri, Huang Shi and mulberry leaf three simultaneously with
Other components coordinate, and the effect of reducing blood lipid is especially pronounced.
The foregoing is only presently preferred embodiments of the present invention, be not intended to limit the invention, it is all the present invention spirit and
Within principle, any modification, equivalent substitution and improvements made etc., it should be included in the scope of the protection.
Claims (7)
1. a kind of pharmaceutical composition of reducing blood lipid, it is characterised in that described pharmaceutical composition includes following raw material：Radix bupleuri, Huang Shi,
Mulberry leaf, the root of kudzu vine, Poria cocos, the red sage root, radix glycyrrhizae, franchet groundcherry persistent calyx or fruit, radish seed, ROUFURONG.
A kind of 2. pharmaceutical composition of reducing blood lipid according to claim 1, it is characterised in that described pharmaceutical composition it is each
Raw material is formed by following parts by weight：Radix bupleuri 20-35 parts, Huang Shi 15-30 parts, mulberry leaf 10-25 parts, root of kudzu vine 10-20 parts, Poria cocos 10-
20 parts, red sage root 10-15 parts, radix glycyrrhizae 10-15 parts, franchet groundcherry persistent calyx or fruit 5-10 parts, radish seed 5-10 parts, ROUFURONG 5-10 parts.
A kind of 3. pharmaceutical composition of reducing blood lipid according to claim 1, it is characterised in that described pharmaceutical composition it is each
Raw material is formed by following parts by weight：It is 25 parts of radix bupleuri, 25 parts of Huang Shi, 20 parts of mulberry leaf, 15 parts of the root of kudzu vine, 15 parts of Poria cocos, 13 parts of the red sage root, sweet
13 parts of grass, 8 parts of franchet groundcherry persistent calyx or fruit, 8 parts of radish seed, 8 parts of ROUFURONG.
A kind of 4. pharmaceutical composition of reducing blood lipid according to any one of claims 1 to 3, it is characterised in that：The medicine
Application of the composition in the medicine for preparing prevention and/or treatment hyperlipemia.
A kind of 5. pharmaceutical composition of reducing blood lipid according to claim 1, it is characterised in that：The agent of described pharmaceutical composition
Type is granule, tablet, pulvis, paste, capsule.
A kind of 6. pharmaceutical composition of reducing blood lipid according to claim 5, it is characterised in that：The formulation is granule.
A kind of 7. pharmaceutical composition of reducing blood lipid according to claim 6, it is characterised in that the specific system of the granule
Standby process is as follows：
(1) each raw material is mixed, then ultramicro grinding；
(2) suitable quantity of water is added in above-mentioned Ultramicro-powder to be mediated；
(3) medicine after above-mentioned kneading is granulated by comminutor；
(4) above-mentioned granule medicament is dried, whole grain, granule is made in packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711082773.9A CN107714823A (en) | 2017-11-07 | 2017-11-07 | A kind of pharmaceutical composition of reducing blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711082773.9A CN107714823A (en) | 2017-11-07 | 2017-11-07 | A kind of pharmaceutical composition of reducing blood lipid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107714823A true CN107714823A (en) | 2018-02-23 |
Family
ID=61221631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711082773.9A Pending CN107714823A (en) | 2017-11-07 | 2017-11-07 | A kind of pharmaceutical composition of reducing blood lipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107714823A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883569A (en) * | 2006-05-26 | 2006-12-27 | 李继业 | Chinese medicinal health product |
| CN102205046A (en) * | 2011-05-11 | 2011-10-05 | 李�杰 | Medicament for reducing blood fat |
-
2017
- 2017-11-07 CN CN201711082773.9A patent/CN107714823A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883569A (en) * | 2006-05-26 | 2006-12-27 | 李继业 | Chinese medicinal health product |
| CN102205046A (en) * | 2011-05-11 | 2011-10-05 | 李�杰 | Medicament for reducing blood fat |
Non-Patent Citations (2)
| Title |
|---|
| 李秀才: "《高血脂症自然疗法》", 30 April 2017, 河南科学技术出版社 * |
| 臧俊歧，等: "《膳食内调 穴位外治"三高"》", 30 April 2016 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105434648A (en) | Traditional Chinese medicine composition for treating acute mastitis and preparation method thereof | |
| CN104984297A (en) | Application of pharmaceutical composition in preparation of drugs for treating amenorrhea | |
| CN104606352A (en) | Bone tuberculosis treating compound pill | |
| CN107789484B (en) | Traditional Chinese medicine composition for treating irregular menstruation and preparation method thereof | |
| CN106924374B (en) | Composition, preparation method thereof and application of composition in preparation of products for reducing blood sugar and/or blood fat | |
| CN102327452A (en) | Chinese patent medicament and Chinese decoction for treating initial carbuncle | |
| CN103751547B (en) | Chinese medicine composition of a kind of blood fat reducing and preparation method thereof | |
| CN103463464A (en) | Health care medicinal wine | |
| CN101249255B (en) | Proprietary Chinese medicine for curing children's cough and method of preparing the same | |
| CN104189251A (en) | Traditional Chinese medicine composition for treating hyperplasia of mammary glands and benign breast tumors and preparation method of traditional Chinese medicine composition | |
| CN107714823A (en) | A kind of pharmaceutical composition of reducing blood lipid | |
| CN106267028A (en) | A kind of Chinese medicine composition treating pneumonia and preparation method thereof | |
| CN102526509B (en) | Medicine for treating hepatomegaly | |
| CN111870656A (en) | Traditional Chinese medicine composition for enhancing immunity and preparation method and application thereof | |
| CN106620475B (en) | Traditional Chinese medicine composition for preventing and treating diabetes cognitive impairment and preparation method thereof | |
| CN104491585A (en) | Paste with effects of expelling wind and removing dampness for rheumatic arthritis and preparation method of paste | |
| CN103919888A (en) | Composite hair tonic and preparation method thereof | |
| CN104225282A (en) | Traditional Chinese medicine for treating postpartum headache | |
| CN104208168B (en) | A kind of for compound traditional Chinese medicine composite treating poultry respiratory infection and preparation method thereof | |
| CN105582379A (en) | Traditional Chinese medicine composition for treating liver-stomach disharmony and preparation method of traditional Chinese medicine composition | |
| CN105362570A (en) | Medicine composition for treating contrast agent extravasation | |
| CN105168834A (en) | Medicine for treating scrofula and preparation method thereof | |
| CN104258211A (en) | Traditional Chinese medicine composition for preventing and treating bovine ephemeral fever and preparation method of traditional Chinese medicine composition | |
| CN102579875B (en) | Liver-protecting bamboo-shoot product and preparation method thereof | |
| CN116966239A (en) | Medicine for treating thyroid cyst and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180223 |
|
| RJ01 | Rejection of invention patent application after publication |